Teriflunomide is a New Multiple Sclerosis Drug Treatment from drug manufacturer Sanofi-Aventis that doctors and patients hope can soon be added to the arsenal of drug weapons to fight the disease that afflicts more than 400,000 patients in the United States alone.

In a Canadian study, patients with the relapsing-remitting form of MS (RRMS) were randomly appointed to take either the Teriflunomide pill or a placebo.  The group taking the oral multiple sclerosis drug had a 31 % reduction in their relapse rates when compared to the placebo group.

Another study, conducted concurrently in these Multiple Sclerosis drug trials, tested the drug at different dosing levels.  It was concluded that the progression of the disease was reduced by almost 30% in the group taking the drug at the higher of the two levels.

These levels of relapse reduction and disease progression reduction are not particularly remarkable when taken alone. There …